Takeda sells €1.5 billion European drugs; top Indian drugmakers expand in China; Eisai moves closer to a quick Alzheimer’s blood test.
For just the second time, the DOJ indicted an opioid distributor for its role in illegally pushing pills at the height of the addiction epidemic.
When AstraZeneca sold its Avlon, England plant in 2016, it thought its liabilities were over. Former employees said the drugmaker broke its promises.
Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.
Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps.
A buyer could emerge from private equity funds, European pharma players and Indian or Asian drugmakers looking to expand in Europe.
Being a top biopharma executive does have its perks—not the least of which is use of the company jet. Who topped 2018’s frequent flyer list?
Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.
After radio silence on its long-running kickback lawsuit, Novartis appears to be approaching a settlement—and it could cost at least $700 million.
Contradicting analysts' observations, Novartis CEO dubbed Zolgensma “one of the most successful launches from an access standpoint in rare diseases.”
